Overview

CP-751,871 Treatment For Patients With Multiple Myeloma

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
0
Participant gender:
All
Summary
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Antibodies, Monoclonal
Criteria
Inclusion Criteria:

- Previously treated multiple myeloma with a quantifiable serum (M spike ≥ 1 g/dL)
and/or urine (≥ 200 mg/24-hr) paraprotein

- Adequate bone marrow, renal, liver and cardiac function

- Eastern Cooperative Oncology Group [ECOG] performance status less than or equal to 2

Exclusion Criteria:

- Prior allogeneic stem cell transplant (alloSCT)

- Myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with
CP-751,871

- Prior organ allograft

- Concurrent use of insulin, oral hypoglycemic medication, growth hormone (GH), or
growth hormone inhibitors

- Female patients who are pregnant or lactating